Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 5/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1028457 | 0.84 | CYP2C9 (0.50) | CACNA1BCACNA1HCYP1A2CYP2C9LMNA | |
| SCHEMBL1075767 | 0.82 | CACNA1B (0.49) | CACNA1BCACNA1HCYP1A2CYP2C9LMNA | |
| SCHEMBL1074016 | 0.78 | CACNA1B (0.46) | CACNA1BCACNA1HCYP1A2CYP2C9LMNA | |
| SCHEMBL3514343 | 0.77 | CYP2C9 (0.55) | CYP1A2CYP2C9LMNAHTTSMN1; SMN2 | |
| SCHEMBL3035703 | 0.76 | LMNA (0.56) | CYP1A2CYP2C9LMNAHTTSMN1; SMN2 | |
| SCHEMBL13034743 | 0.76 | CYP2C9 (0.52) | CYP1A2CYP2C9LMNAMCL1 | |
| SCHEMBL3512721 | 0.74 | CYP2C9 (0.52) | CYP1A2CYP2C9LMNAHTTSMN1; SMN2 | |
| SCHEMBL3512980 | 0.72 | CYP2C9 (0.72) | CYP1A2CYP2C9LMNAHTTSMN1; SMN2 | |
| SCHEMBL3511872 | 0.72 | CYP2C9 (0.57) | CYP1A2CYP2C9LMNAHTTSMN1; SMN2 | |
| SCHEMBL3514314 | 0.72 | CYP2C9 (0.49) | CYP1A2CYP2C9LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071197-A1 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | BIOLIPOX AB (LV) | 2011-03-24 | — | — | US | disclosed |
| EP-2274280-A2 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | Biolipox AB (SE) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009127822-A2 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | BIOLIPOX AB (SE) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071197-A1 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | LTC4S, LTB4R2, LTB4R | CACNA1B 2956/4885CACNA1H 3075/4885CYP1A2 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.